Orthofix Medical Inc. (NASDAQ:OFIX) Insider Lucas Vitale Sells 4,287 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) insider Lucas Vitale sold 4,287 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total transaction of $71,164.20. Following the completion of the transaction, the insider now owns 135,317 shares in the company, valued at $2,246,262.20. This represents a 3.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Orthofix Medical Stock Performance

OFIX opened at $16.90 on Friday. The stock has a market capitalization of $659.47 million, a price-to-earnings ratio of -5.40 and a beta of 1.06. Orthofix Medical Inc. has a fifty-two week low of $12.08 and a fifty-two week high of $20.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The company has a fifty day moving average of $17.78 and a 200 day moving average of $17.37.

Hedge Funds Weigh In On Orthofix Medical

Several large investors have recently modified their holdings of OFIX. Lazard Asset Management LLC bought a new position in Orthofix Medical in the 4th quarter worth about $45,000. R Squared Ltd bought a new stake in shares of Orthofix Medical in the 4th quarter valued at about $50,000. KLP Kapitalforvaltning AS purchased a new position in Orthofix Medical in the fourth quarter worth $112,000. Tower Research Capital LLC TRC increased its position in Orthofix Medical by 120.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company’s stock valued at $148,000 after buying an additional 4,627 shares in the last quarter. Finally, State of Wyoming raised its position in shares of Orthofix Medical by 206.8% in the 4th quarter. State of Wyoming now owns 9,432 shares of the medical device company’s stock valued at $165,000 after purchasing an additional 6,358 shares during the last quarter. Institutional investors own 89.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OFIX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $24.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, February 25th. Finally, Roth Mkm restated a “buy” rating and issued a $22.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.